Cue Biopharma is expected to report a third-quarter 2026 loss of $2.24 per share on revenue of $1.03 million, with the current stock price of $18.27 trading significantly below the average analyst price target of $83.00.
Investors are primarily focused on the company’s cash runway and clinical momentum for its lead asset, CUE-221, following positive Phase 2 topline results in chronic spontaneous urticaria. This earnings report follows a strategic realignment toward allergic and autoimmune diseases, supported by a $50 million private placement completed in July 2026. Management's guidance on the upcoming Phase 2b/3 trial initiation and the Phase 1 start for CUE-401 will be critical for assessing the company's long-term capital strategy.